BRPI0923583A2 - síntese de conjugados de polímeros de compostos de indocarbzol. - Google Patents
síntese de conjugados de polímeros de compostos de indocarbzol.Info
- Publication number
- BRPI0923583A2 BRPI0923583A2 BRPI0923583A BRPI0923583A BRPI0923583A2 BR PI0923583 A2 BRPI0923583 A2 BR PI0923583A2 BR PI0923583 A BRPI0923583 A BR PI0923583A BR PI0923583 A BRPI0923583 A BR PI0923583A BR PI0923583 A2 BRPI0923583 A2 BR PI0923583A2
- Authority
- BR
- Brazil
- Prior art keywords
- indocarbzole
- synthesis
- compounds
- polymer conjugates
- conjugates
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 229920000642 polymer Polymers 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
- C07D243/30—Preparation including building-up the benzodiazepine skeleton from compounds already containing hetero rings
- C07D243/36—Preparation including building-up the benzodiazepine skeleton from compounds already containing hetero rings containing an indole or hydrogenated indole ring system
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13981608P | 2008-12-22 | 2008-12-22 | |
US15205509P | 2009-02-12 | 2009-02-12 | |
PCT/EP2009/067817 WO2010072795A1 (en) | 2008-12-22 | 2009-12-22 | Synthesis of polymer conjugates of indolocarbazole compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0923583A2 true BRPI0923583A2 (pt) | 2018-10-09 |
Family
ID=42014352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0923583A BRPI0923583A2 (pt) | 2008-12-22 | 2009-12-22 | síntese de conjugados de polímeros de compostos de indocarbzol. |
Country Status (26)
Country | Link |
---|---|
US (1) | US8926955B2 (pt) |
EP (1) | EP2381964B1 (pt) |
JP (1) | JP5579197B2 (pt) |
KR (1) | KR101431165B1 (pt) |
CN (1) | CN102264398B (pt) |
AU (1) | AU2009331490C1 (pt) |
BR (1) | BRPI0923583A2 (pt) |
CA (1) | CA2747838C (pt) |
CY (1) | CY1115529T1 (pt) |
DK (1) | DK2381964T3 (pt) |
ES (1) | ES2484000T3 (pt) |
HK (1) | HK1162978A1 (pt) |
HR (1) | HRP20140836T1 (pt) |
IL (1) | IL213516A (pt) |
MX (1) | MX2011006456A (pt) |
MY (1) | MY171292A (pt) |
NZ (1) | NZ593438A (pt) |
PL (1) | PL2381964T3 (pt) |
PT (1) | PT2381964E (pt) |
RS (1) | RS53530B1 (pt) |
RU (1) | RU2532341C2 (pt) |
SG (1) | SG172346A1 (pt) |
SI (1) | SI2381964T1 (pt) |
SM (1) | SMT201400141B (pt) |
WO (1) | WO2010072795A1 (pt) |
ZA (1) | ZA201104289B (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014177510A2 (en) * | 2013-05-03 | 2014-11-06 | Creabilis Sa | Polymer conjugates of indolocarbazole compounds in the treatment of pruritus |
JP6445802B2 (ja) * | 2014-07-16 | 2018-12-26 | 学校法人慶應義塾 | インフラマソーム活性化制御物質のスクリーニング方法 |
WO2018175301A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugate of montesanib with reduced exposure |
WO2018175315A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugates of staurosporine derivatives having reduced exposure |
EP3600440A1 (en) | 2017-03-20 | 2020-02-05 | Sienna Biopharmaceuticals, Inc. | Reduced exposure conjugates modulating therapeutic targets |
WO2018175302A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugates targeting c-src with reduced exposure |
WO2018208369A1 (en) | 2017-05-10 | 2018-11-15 | Sienna Biopharmaceuticals, Inc. | Uses of polymer conjugates of indolocarbazole compounds with reduced exposure |
US20190209472A1 (en) * | 2017-12-04 | 2019-07-11 | Sienna Biopharmaceuticals, Inc. | Formulations for dermal delivery of polymer conjugates of indolocarbazole compounds with reduced exposure |
WO2020023387A1 (en) * | 2018-07-23 | 2020-01-30 | Sienna Biopharmaceuticals, Inc. | Uses of polymer conjugates of indolocarbazole compounds with reduced exposure |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
WO1993024476A1 (en) | 1992-06-04 | 1993-12-09 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
US6326353B1 (en) | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
US5468872A (en) | 1993-09-16 | 1995-11-21 | Cephalon, Inc. | K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders |
UA67725C2 (en) * | 1996-06-03 | 2004-07-15 | Cephalon Inc | K-252a derivatives and a method for improvement of functioning and cell survival enhancement |
US20060210553A1 (en) | 2003-07-23 | 2006-09-21 | Creabilis Therapeutics S.R.L. | Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excesssive cell proliferation |
AU2005259381A1 (en) | 2004-07-02 | 2006-01-12 | Creabilis Therapeutics S.P.A. | Nucleic acids for the treatment of HMGB1-related pathologies |
EA017318B1 (ru) * | 2005-08-25 | 2012-11-30 | Креабилис Терапеутикс С.П.А. | Полимерные конъюгаты индолокарбазола и его производных |
-
2009
- 2009-12-22 EP EP09795791.4A patent/EP2381964B1/en active Active
- 2009-12-22 WO PCT/EP2009/067817 patent/WO2010072795A1/en active Application Filing
- 2009-12-22 CN CN2009801521111A patent/CN102264398B/zh not_active Expired - Fee Related
- 2009-12-22 CA CA2747838A patent/CA2747838C/en not_active Expired - Fee Related
- 2009-12-22 US US13/141,354 patent/US8926955B2/en active Active
- 2009-12-22 MY MYPI2011002907A patent/MY171292A/en unknown
- 2009-12-22 BR BRPI0923583A patent/BRPI0923583A2/pt not_active Application Discontinuation
- 2009-12-22 SG SG2011046133A patent/SG172346A1/en unknown
- 2009-12-22 MX MX2011006456A patent/MX2011006456A/es active IP Right Grant
- 2009-12-22 ES ES09795791.4T patent/ES2484000T3/es active Active
- 2009-12-22 JP JP2011542820A patent/JP5579197B2/ja active Active
- 2009-12-22 AU AU2009331490A patent/AU2009331490C1/en active Active
- 2009-12-22 KR KR1020117016563A patent/KR101431165B1/ko active IP Right Grant
- 2009-12-22 PL PL09795791T patent/PL2381964T3/pl unknown
- 2009-12-22 SI SI200931010T patent/SI2381964T1/sl unknown
- 2009-12-22 NZ NZ593438A patent/NZ593438A/xx not_active IP Right Cessation
- 2009-12-22 RU RU2011130512/04A patent/RU2532341C2/ru active
- 2009-12-22 PT PT97957914T patent/PT2381964E/pt unknown
- 2009-12-22 DK DK09795791.4T patent/DK2381964T3/da active
- 2009-12-22 RS RSP20140464 patent/RS53530B1/en unknown
-
2011
- 2011-06-09 ZA ZA2011/04289A patent/ZA201104289B/en unknown
- 2011-06-13 IL IL213516A patent/IL213516A/en not_active IP Right Cessation
-
2012
- 2012-04-20 HK HK12103942.9A patent/HK1162978A1/xx not_active IP Right Cessation
-
2014
- 2014-09-04 HR HRP20140836AT patent/HRP20140836T1/hr unknown
- 2014-09-08 CY CY20141100720T patent/CY1115529T1/el unknown
- 2014-09-25 SM SM201400141T patent/SMT201400141B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0815042A2 (pt) | Compostos de pirazol | |
DK2288375T3 (da) | Pegylerede insulin-lispro-forbindelser | |
BRPI0920707A2 (pt) | compostos | |
DK2242759T3 (da) | Forbindelser | |
BRPI0908982A2 (pt) | síntese de carbonetos cíclicos | |
BRPI0815717A2 (pt) | Compostos de imidazopirazina. | |
BRPI0818373A2 (pt) | compostos de pelicetal, síntese e aplicações | |
BRPI0917113A2 (pt) | composições polimpericas flavorizadas otimizadas | |
BRPI0923583A2 (pt) | síntese de conjugados de polímeros de compostos de indocarbzol. | |
BRPI0911849A2 (pt) | protetores solares | |
BRPI0913832A2 (pt) | derivados de pirrolopiridinilpirimidin-2-ilamina | |
BRPI0815246A2 (pt) | Composição de catalisador | |
DK2323972T3 (da) | C7-fluor-substituerede tetracylinforbindelser | |
DE602008001230D1 (de) | Verbesserte Polymerzusammensetzung | |
BRPI0914942A2 (pt) | Compostos de oxindol | |
DK2297162T3 (da) | Forbindelser | |
BRPI0906357A2 (pt) | Derivados de oxazepinopirimidona arilamida substituídos | |
BRPI0917446A2 (pt) | derivados de acilaminobenzamida. | |
BRPI0913234A2 (pt) | derivados de tiazolilpiperidina | |
BRPI0906714A2 (pt) | Derivados de oxazepinopirimidona heteroarilamida substituídos. | |
BRPI0916432A2 (pt) | compostos | |
DK2271618T3 (da) | Farmaceutiske forbindelser | |
BRPI0911393A2 (pt) | composto de 5-hidroxipirimidina-4-carboxamida | |
BRPI0907448A2 (pt) | Instrumentos. | |
DK2206698T3 (da) | Ethynylindolforbindelser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |